SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Jack London Synthetic CCD

PatientJack London
Date of birth1987-01-12
IdentifiersMRN HR-ET010-SYN; SSN (made up) 000-10-4482
Document date2026-11-01
AuthorEleanor Whitcombe-Ibe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Establishing care for tiredness and ankle swelling, with high blood pressure and abnormal kidney tests, and heavy drinking found at the visit: kidney, liver and alcohol tests, AUDIT and DSM-5-TR assessment, withdrawal planning, mood and safety, his writing schedule, and a nephrology consultation. Concerns: Tired by afternoon, with swollen ankles, and frightened by the word 'kidneys' again; He knows the drinking is hurting him and wants to stop without losing his work; He wants to keep writing a thousand words every morning. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naproxen 500 mg oral tablet twice daily, bought over the counter at full strength and taken most days for about two years for knee and back pain; stopped at intakeOne tablet by mouth twice a day, self-directedOral route2024-08-01 to 2026-08-04stoppedS
Losartan 50 mg oral tablet once dailyOne tablet by mouth every morningOral route2026-08-04 to 2026-09-15completedS
Losartan 100 mg oral tablet once dailyOne tablet by mouth every morningOral route2026-09-15activeS
Chlordiazepoxide 25 mg oral capsule, fixed five-day taper for alcohol withdrawal (four capsules on day 1, three on day 2, two on day 3, one on days 4 and 5), dispensed for five days only, with a daily telephone checkUp to one capsule four times a day on day 1, tapering to one a day by day 4; stop after day 5; no alcohol or drivingOral route2026-08-04 to 2026-08-08completedS
Thiamine 100 mg oral tablet once dailyOne tablet by mouth dailyOral route2026-08-04activeS
Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxenOne to two tablets by mouth every six hours as needed; no more than four tablets a dayOral route2026-08-04activeS
Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicinesOne tablet by mouth every morningOral route2026-08-18activeS
Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once dailyOne tablet by mouth dailyOral route2026-09-15activeS
Dapagliflozin 10 mg oral tablet once daily, held on any day he cannot eat or drink normally, and before surgeryOne tablet by mouth every morning; sick-day rules in writingOral route2026-10-13activeS
Diclofenac 1% gel, 4 g rubbed into the outer right ankle four times a day for up to seven days, in place of any oral anti-inflammatory medicineApply 4 g to the ankle four times a day for up to seven daysTopical route2026-09-01 to 2026-09-08completedS

Procedures

ProcedureDatesStatusEvidence
Ultrasound of the abdomen and kidneys: right kidney 10.8 cm and left 11.0 cm with increased cortical echogenicity and preserved cortical thickness, no stones, no hydronephrosis, no cysts; bright liver consistent with steatosis, smooth outline, normal spleen, no ascites2026-08-18 to 2026-08-18completedS
Vibration-controlled transient elastography of the liver: median liver stiffness 7.2 kPa (interquartile range under 30 percent), controlled attenuation parameter 312 dB/m; advanced fibrosis unlikely2026-08-18 to 2026-08-18completedS
Advance care planning conversation, about 20 minutes2026-09-29 to 2026-09-29completedS

Immunizations

DateVaccineStatusEvidence
2026-09-29Influenza vaccine, inactivated, trivalent, preservative-free, for this seasoncompletedS
2026-09-29Pneumococcal conjugate vaccine (PCV20), single dosecompletedS
2026-09-29Hepatitis B vaccine (HepB-CpG), first of two dosescompletedS
2026-09-29Hepatitis A vaccine, adult, first of two dosescompletedS
2026-10-27Hepatitis B vaccine (HepB-CpG), second of two dosescompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1897 to 1898Scurvy in the gold fields in his early twenties; recoveredD (CLM-0003)
1907 to 1909Skin sores, swollen and peeling hands and feet, and a silvery skin during a long Pacific voyage, with five weeks in hospital; the hands recovered and the skin cleared without treatment; the diagnoses were never settledR (CLM-0006, CLM-0007)
July 1913Appendectomy, at which kidney damage was foundD (CLM-0009)
1914Dysentery and joint pain (described as rheumatism) while working abroadD (CLM-0010)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
Tired by afternoon, with swollen ankles, and frightened by the word 'kidneys' againactiveS
He knows the drinking is hurting him and wants to stop without losing his workactiveS
He wants to keep writing a thousand words every morningactiveS

Assessment

Most recent measures: Sodium [Moles/volume] in Serum or Plasma 139 on 2026-10-27; Potassium [Moles/volume] in Serum or Plasma 4.7 on 2026-10-27; Carbon dioxide, total [Moles/volume] in Serum or Plasma 23 on 2026-10-27; Urea nitrogen [Mass/volume] in Serum or Plasma 24 on 2026-10-27; Creatinine [Mass/volume] in Serum or Plasma 2.13 on 2026-10-27; Glucose [Mass/volume] in Serum or Plasma 94 on 2026-08-04; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 40 on 2026-10-27; Albumin/Creatinine [Mass Ratio] in Urine 96 on 2026-10-27; Urate [Mass/volume] in Serum or Plasma 8.4 on 2026-08-04; Calcium [Mass/volume] in Serum or Plasma 9.2 on 2026-08-04; Phosphate [Mass/volume] in Serum or Plasma 3.8 on 2026-08-04; Parathyrin.intact [Mass/volume] in Serum or Plasma 74 on 2026-08-04; Hemoglobin [Mass/volume] in Blood 13.6 on 2026-08-04; MCV [Entitic mean volume] in Red Blood Cells by Automated count 96 on 2026-10-27; Platelets [#/volume] in Blood by Automated count 182 on 2026-08-04; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 on 2026-10-27; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 on 2026-10-27; Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma 54 on 2026-10-27; Albumin [Mass/volume] in Serum or Plasma 4.1 on 2026-08-04; Bilirubin.total [Mass/volume] in Serum or Plasma 0.9 on 2026-08-04; INR in Platelet poor plasma by Coagulation assay 1 on 2026-08-04; Phosphatidylethanol [Mass/volume] in Blood 6 on 2026-10-27; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 2026-08-04; Cholesterol [Mass/volume] in Serum or Plasma 214 on 2026-08-04; Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 on 2026-08-04; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 128 on 2026-08-04; Triglyceride [Mass/volume] in Serum or Plasma 140 on 2026-08-04; Total score [AUDIT] 9 on 2026-10-27; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-10-27; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 4 on 2026-10-27; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 24 on 2026-09-15; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-09-29 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Tiredness, ankle swelling and high blood pressure (158/98 mmHg) with a raised creatinine (1.98 mg/dL, eGFR 43) and albumin in the urine (240 mg/g), found at intake; a creatinine of 1.7 mg/dL at an insurance examination about fourteen months ago, by his account; chronicity and cause under evaluation with a nephrology consultationresolvedconfirmed R94.4S — Synthetic presenting problem anchored to the documented kidney damage found in 1913; superseded when the consultation staged chronic kidney disease.
Chronic kidney disease, stage G3b A2 (eGFR 42 to 43, urine albumin 240 mg/g), most likely from hypertension with a contribution from two years of daily naproxen; kidneys of normal size, without stones or obstruction; urine sediment bland; synthetic modern diagnosis linked to his documented kidney diseaseactiveconfirmed N18.32S — Synthetic modern diagnosis made at the consultation, anchored to his documented kidney damage and death from uraemia; the cause in the modern episode is synthetic and is not a claim about his real kidneys.
Hypertensive chronic kidney disease, untreated until intakeactiveconfirmed I12.9S — Synthetic modern diagnosis made at the consultation.
Alcohol use disorder, severe (seven DSM-5-TR criteria): a bottle of whisky or more most days for years, a morning drink to steady his hands, failed attempts to cut down, and drinking despite knowing it harms his health; AUDIT 27; PEth 410 ng/mLactiveconfirmed F10.20S — Synthetic modern diagnosis anchored to his own published account of heavy drinking; the criteria, scores and amounts are synthetic and are not a claim about his real drinking.
Alcohol-associated fatty liver without advanced fibrosis (liver stiffness 7.2 kPa; steatosis on ultrasound); FIB-4 2.28 at intakeactiveconfirmed K70.0S — Synthetic finding of the ultrasound and elastography at the consultation; not a claim about his real liver.
Daily self-directed naproxen for knee and back pain for about two years, stopped at intake; acetaminophen in its placeresolvedconfirmed Z79.1S — Synthetic medication history; the joint pain is anchored to the documented rheumatism of 1914, which is not given a diagnosis.
Cigarette smoking, about ten a day; not ready to stop while he stops drinkingactiveconfirmed F17.210S — Synthetic tobacco use; a physician-author's suggestion of heavy tobacco use is recorded only as a retrospective claim.
Right ankle sprain (lateral ligaments, moderate), from stepping into a burrow while walking the pasture; Ottawa ankle rules negative; healed in about four weeksresolvedconfirmed S93.401AS — Synthetic acute injury; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-04Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-08-04Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-08-04Carbon dioxide, total [Moles/volume] in Serum or Plasma22mmol/L22-29 mmol/LNormalS
2026-08-04Urea nitrogen [Mass/volume] in Serum or Plasma28mg/dL7-20 mg/dLHighS
2026-08-04Creatinine [Mass/volume] in Serum or Plasma1.98mg/dL0.74-1.35 mg/dLHighS
2026-08-04Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2026-08-04Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M43mL/min/{1.73_m2}45 to 59 is G3a; 30 to 44 is G3bLowS
2026-08-04Albumin/Creatinine [Mass Ratio] in Urine240mg/gBelow 30 mg/g A1; 30 to 300 A2; above 300 A3HighS
2026-08-04Urate [Mass/volume] in Serum or Plasma8.4mg/dL4-8 mg/dLHighS
2026-08-04Calcium [Mass/volume] in Serum or Plasma9.2mg/dL8.6-10.3 mg/dLNormalS
2026-08-04Phosphate [Mass/volume] in Serum or Plasma3.8mg/dL2.5-4.5 mg/dLNormalS
2026-08-04Parathyrin.intact [Mass/volume] in Serum or Plasma74pg/mL15-65 pg/mLHighS
2026-08-04Hemoglobin [Mass/volume] in Blood13.6g/dL13-17 g/dLNormalS
2026-08-04MCV [Entitic mean volume] in Red Blood Cells by Automated count101fL80-100 fLHighS
2026-08-04Platelets [#/volume] in Blood by Automated count18210*3/uL150-400 10*3/uLNormalS
2026-08-04Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma68U/L10-40 U/LHighS
2026-08-04Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma41U/L9-46 U/LNormalS
2026-08-04Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma186U/L8-61 U/LHighS
2026-08-04Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2026-08-04Bilirubin.total [Mass/volume] in Serum or Plasma0.9mg/dL0.2-1.2 mg/dLNormalS
2026-08-04INR in Platelet poor plasma by Coagulation assay1{INR}0.9-1.1NormalS
2026-08-04Phosphatidylethanol [Mass/volume] in Blood410ng/mLBelow 20 ng/mL abstinence or light drinking; above 200 heavy drinkingHighS
2026-08-04Hemoglobin A1c/Hemoglobin.total in Blood5.4%<=5.6%NormalS
2026-08-04Cholesterol [Mass/volume] in Serum or Plasma214mg/dL<=199 mg/dLHighS
2026-08-04Cholesterol in HDL [Mass/volume] in Serum or Plasma58mg/dL>=40 mg/dLNormalS
2026-08-04Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation128mg/dL<=129 mg/dLNormalS
2026-08-04Triglyceride [Mass/volume] in Serum or Plasma140mg/dL<=149 mg/dLNormalS
2026-08-04Total score [AUDIT]27{score}S
2026-08-04Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]9{score}S
2026-08-04Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]7{score}S
2026-08-18Potassium [Moles/volume] in Serum or Plasma4.9mmol/L3.5-5.1 mmol/LNormalS
2026-08-18Creatinine [Mass/volume] in Serum or Plasma2.04mg/dL0.74-1.35 mg/dLHighS
2026-08-18Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M42mL/min/{1.73_m2}45 to 59 is G3a; 30 to 44 is G3bLowS
2026-08-18Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma49U/L10-40 U/LHighS
2026-08-18Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma36U/L9-46 U/LNormalS
2026-08-18Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma141U/L8-61 U/LHighS
2026-09-15Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-09-15Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
2026-09-15Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
2026-09-15Creatinine [Mass/volume] in Serum or Plasma1.96mg/dL0.74-1.35 mg/dLHighS
2026-09-15Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M44mL/min/{1.73_m2}45 to 59 is G3a; 30 to 44 is G3bLowS
2026-09-15Albumin/Creatinine [Mass Ratio] in Urine128mg/gBelow 30 mg/g A1; 30 to 300 A2; above 300 A3HighS
2026-09-15Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma34U/L10-40 U/LNormalS
2026-09-15Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L9-46 U/LNormalS
2026-09-15Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma82U/L8-61 U/LHighS
2026-09-15Phosphatidylethanol [Mass/volume] in Blood36ng/mLBelow 20 ng/mL abstinence or light drinking; above 200 heavy drinkingHighS
2026-09-1525-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma24ng/mLBelow 20 ng/mL deficient; 20 to 29 insufficientLowS
2026-09-15Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
2026-09-29Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-10-13Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-10-13Potassium [Moles/volume] in Serum or Plasma5mmol/L3.5-5.1 mmol/LNormalS
2026-10-13Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
2026-10-13Creatinine [Mass/volume] in Serum or Plasma1.95mg/dL0.74-1.35 mg/dLHighS
2026-10-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M44mL/min/{1.73_m2}45 to 59 is G3a; 30 to 44 is G3bLowS
2026-10-13Phosphatidylethanol [Mass/volume] in Blood8ng/mLBelow 20 ng/mL abstinence or light drinking; above 200 heavy drinkingNormalS
2026-10-27Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-10-27Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
2026-10-27Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
2026-10-27Urea nitrogen [Mass/volume] in Serum or Plasma24mg/dL7-20 mg/dLHighS
2026-10-27Creatinine [Mass/volume] in Serum or Plasma2.13mg/dL0.74-1.35 mg/dLHighS
2026-10-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M40mL/min/{1.73_m2}45 to 59 is G3a; 30 to 44 is G3bLowS
2026-10-27Albumin/Creatinine [Mass Ratio] in Urine96mg/gBelow 30 mg/g A1; 30 to 300 A2; above 300 A3HighS
2026-10-27Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L10-40 U/LNormalS
2026-10-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L9-46 U/LNormalS
2026-10-27Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma54U/L8-61 U/LNormalS
2026-10-27MCV [Entitic mean volume] in Red Blood Cells by Automated count96fL80-100 fLNormalS
2026-10-27Phosphatidylethanol [Mass/volume] in Blood6ng/mLBelow 20 ng/mL abstinence or light drinking; above 200 heavy drinkingNormalS
2026-10-27Total score [AUDIT]9{score}S
2026-10-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-10-27Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]4{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-08-04Body height173cmS
2026-08-04Body weight84.2kgS
2026-08-04Body mass index (BMI) [Ratio]28.1kg/m2S
2026-08-04Systolic blood pressure158mm[Hg]S
2026-08-04Diastolic blood pressure98mm[Hg]S
2026-08-04Heart rate92/minS
2026-08-04Respiratory rate16/minS
2026-08-04Body temperature36.8CelS
2026-08-04Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-08-18Body height173cmS
2026-08-18Body weight83.6kgS
2026-08-18Body mass index (BMI) [Ratio]27.9kg/m2S
2026-08-18Systolic blood pressure146mm[Hg]S
2026-08-18Diastolic blood pressure92mm[Hg]S
2026-08-18Heart rate84/minS
2026-08-18Respiratory rate16/minS
2026-08-18Body temperature36.6CelS
2026-08-18Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-09-15Body height173cmS
2026-09-15Body weight82.6kgS
2026-09-15Body mass index (BMI) [Ratio]27.6kg/m2S
2026-09-15Systolic blood pressure138mm[Hg]S
2026-09-15Diastolic blood pressure86mm[Hg]S
2026-09-15Heart rate78/minS
2026-09-15Respiratory rate14/minS
2026-09-15Body temperature36.6CelS
2026-09-15Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-13Body height173cmS
2026-10-13Body weight81.4kgS
2026-10-13Body mass index (BMI) [Ratio]27.2kg/m2S
2026-10-13Systolic blood pressure126mm[Hg]S
2026-10-13Diastolic blood pressure80mm[Hg]S
2026-10-13Heart rate72/minS
2026-10-13Respiratory rate14/minS
2026-10-13Body temperature36.6CelS
2026-10-13Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-27Body height173cmS
2026-10-27Body weight80.9kgS
2026-10-27Body mass index (BMI) [Ratio]27kg/m2S
2026-10-27Systolic blood pressure122mm[Hg]S
2026-10-27Diastolic blood pressure78mm[Hg]S
2026-10-27Heart rate70/minS
2026-10-27Respiratory rate14/minS
2026-10-27Body temperature36.6CelS
2026-10-27Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-09-29Body height173cmS
2026-09-29Body weight82kgS
2026-09-29Body mass index (BMI) [Ratio]27.4kg/m2S
2026-09-29Systolic blood pressure130mm[Hg]S
2026-09-29Diastolic blood pressure82mm[Hg]S
2026-09-29Heart rate74/minS
2026-09-29Respiratory rate14/minS
2026-09-29Body temperature36.6CelS
2026-09-29Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-09-01Body height173cmS
2026-09-01Body weight83.2kgS
2026-09-01Body mass index (BMI) [Ratio]27.8kg/m2S
2026-09-01Systolic blood pressure142mm[Hg]S
2026-09-01Diastolic blood pressure88mm[Hg]S
2026-09-01Heart rate88/minS
2026-09-01Respiratory rate16/minS
2026-09-01Body temperature36.7CelS
2026-09-01Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-08-04Establishing care for tiredness and ankle swelling, with high blood pressure and abnormal kidney tests, and heavy drinking found at the visit: kidney, liver and alcohol tests, AUDIT and DSM-5-TR assessment, withdrawal planning, mood and safety, his writing schedule, and a nephrology consultationfinishedS
2026-08-18Two-week review after stopping alcohol and starting losartan, seen the same day by nephrology: kidney staging and cause, ultrasound and elastography, blood pressure target, medicine for alcohol use disorder, and pain relieffinishedS
2026-09-15Six-week review: drinking and PEth, blood pressure, potassium and creatinine, urine albumin, liver tests, mood and safetyfinishedS
2026-10-13Ten-week review: abstinence, potassium and creatinine after the losartan increase, and the SGLT2 inhibitorfinishedS
2026-10-27Twelve-week review: kidney function after the SGLT2 inhibitor, urine albumin, liver tests, AUDIT, mood, safety and the plan aheadfinishedS
2026-09-29Periodic adult preventive visitfinishedS
2026-09-01Same-day sick visit for a right ankle sprainfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Kidneys and blood pressure: creatinine with eGFR (CKD-EPI 2021), urine albumin-to-creatinine ratio and urinalysis with microscopy, electrolytes and bicarbonate, uric acid, calcium, phosphate and PTH, blood count, HbA1c and a lipid panel once; the earlier insurance creatinine obtained; ultrasound of the kidneys and liver; standardized office blood pressure at every visit and home readingscompletedGL-KDIGO-CKD-2024, GL-KDIGO-BP-2021, GL-CMID-2026S
Nephrology consultation to confirm the stage and cause of the kidney disease and advise on blood pressure, an SGLT2 inhibitor, medicines for alcohol use disorder at his kidney function, and pain reliefcompletedGL-KDIGO-CKD-2024, GL-KDIGO-BP-2021S
Losartan 50 mg daily from intake, raised to the maximum tolerated dose, with potassium and creatinine two to four weeks after each start or change, accepting a rise in creatinine of up to 30 percent; less saltcompletedGL-KDIGO-BP-2021, GL-AHA-HTN-2025, GL-CMID-2026S
Alcohol: AUDIT, DSM-5-TR criteria and PEth with consent; liver tests and FIB-4; a withdrawal-risk score (PAWSS) and outpatient withdrawal with a five-day chlordiazepoxide taper, daily telephone checks and thiamine; addiction-focused counseling with the clinic's addiction medicine team each week and mutual-help meetings if he wishes; PEth and liver tests at follow-upcompletedGL-APA-AUD-2018, GL-SUD-2021, GL-ASAM-AWM-2020, GL-AASLD-NIT-2025S
Medicine for alcohol use disorder: naltrexone 50 mg daily, which needs no dose change at his kidney function, with liver tests and a wallet card about opioid blockade; acamprosate not chosen because it needs a lower dose at his creatinine clearance and is avoided below 30 mL/min, and he could not reliably take it three times a daycompletedGL-APA-AUD-2018, GL-SUD-2021, GL-KDIGO-CKD-2024S
Liver: ultrasound and vibration-controlled transient elastography for an indeterminate FIB-4; abstinence as the treatmentcompletedGL-AASLD-ALD-2019, GL-AASLD-NIT-2025S
SGLT2 inhibitor (dapagliflozin 10 mg daily) once he has been abstinent for some weeks and is eating regularly, because heavy drinking and fasting raise the risk of ketoacidosis; held on days he cannot eat or drink, with potassium and creatinine two to four weeks after starting, accepting an early fall in eGFRcompletedGL-KDIGO-CKD-2024, GL-CMID-2026S
Pain and medicine safety: no naproxen, ibuprofen or other oral anti-inflammatory medicines; acetaminophen up to 2,000 mg a day; no opioids or tramadol with kidney disease and in early recovery, and none at all if naltrexone is started; any new medicine checked for kidney dosingcompletedGL-KDIGO-CKD-2024, GL-CMID-2026S
Safety: a structured safety assessment, firearms locked with ammunition apart, small supplies of withdrawal medicine, a written safety plan, the 988 Suicide & Crisis Lifeline, and safety review at every visitcompletedGL-SUICIDE-2024, GL-USPSTF-DEP-2023S
Work and recovery: keep the morning writing hours from nine to eleven; replace the late-morning drink with a swim or a ride; no alcohol kept in the writing room; PHQ-9 and GAD-7 at intake and follow-upcompletedGL-SUD-2021, GL-USPSTF-DEP-2023S
Tobacco: advice to stop, with nicotine replacement or varenicline offered when he is readycompletedGL-USPSTF-TOB-2021S

Goals

GoalTargetStatusOutcomeProvenance
Find out how much kidney function is lost, how long it has been so, and why2026-08-18completedChronic kidney disease G3b A2 from hypertension with naproxen contributing; no stones, obstruction or glomerular disease suspectedS
Stop drinking safely, and stay stopped2027-02-02activeWithdrawal completed without complications; one evening of drinking at four weeks; abstinent since, with PEth 8 and then 6 ng/mLS
Blood pressure below 120 systolic by standardized office measurement if tolerated, and at least below 130/802027-02-02active158/98 to 122/78 at twelve weeks on losartan 100 mgS
Urine albumin down by at least 30 percent2026-10-27completed240 to 96 mg/g on losartan and then dapagliflozinS
No anti-inflammatory pain medicines, and pain controlled2026-10-27completedNo naproxen since intake; acetaminophen and topical treatment only, including for an ankle sprainS
Keep the morning writing hours2026-10-27completedWrote every morning through the twelve weeks except the two days of the worst withdrawalS

Functional Status

Mental Status

Structured synthetic safety assessment on 2026-08-04: current ideation absent, intent absent, plan absent. Outpatient care with close follow-up. Risk factors reviewed without detail: severe alcohol use disorder, a new chronic illness, financial pressure, mild depressive and anxiety symptoms, and firearms on the ranch. He agreed that the rifle and shotgun will be kept locked in the ranch office safe with the ammunition stored apart, and that he will not handle them after drinking. Chlordiazepoxide is dispensed for five days only, with a daily telephone check. A written safety plan was made with him, and the 988 Suicide & Crisis Lifeline (call or text 988) and the clinic's number were written on a card he carries. Safety is reviewed at every visit [S]